Study ID	Outcome	Arm 1		Arm 2		Arm 3		Comparison pair
		Event or mean (SD)	Total	Event or mean (SD)	Total	Event or mean (SD)	Total
De Leo 2017		Cranberry + noxamicina + D‐mannose (unknown doses)		No treatment		‐		D‐mannose combined with dietary supplements versus no treatment
	Symptomatic‐only UTI (cystitis) Unit: number of patients reporting decrease in symptoms UTI defined as: 'cystitis, with or without bacteriuria'. Time: at 12 weeks Type: "treatment and prevention"	"Slight decrease in symptoms of UTI in 5 participants". Note: not reported from which arm	97	"Slight decrease in symptoms of UTI in 5 participants". Note: not reported from which arm	50	‐	‐
	Cure/complete remission of symptomatic and asymptomatic UTI Unit: number of patients reporting decrease in symptoms UTI defined as: 'cystitis, with or without bacteriuria' undefined in abstract Time: at 12 weeks Type: "treatment and prevention"	"Complete remission of symptoms in 92 women overall". Note: not reported from which arm	100	"Complete remission of symptoms in 92 women overall". Note: not reported from which arm	50	‐	‐
	Adverse events	0	100
Kuzmenko 2019	No appropriate outcome data reported: "relief of dysuric phenomena and pain" in both groups							D‐mannose + antibiotic + prebiotic versus antibiotic + prebiotic
Kranjcec 2014		D‐mannose 2 g		Nitrofurantoin 50 mg (antibiotic)		No treatment		1). D‐mannose versus antibiotics 2). D‐mannose versus no treatment
	Symptomatic and bacteriuria‐confirmed UTI Unit: number of patients reporting a recurrent UTI UTI defined as: confirmed isolated bacteria in acute cystitis Time: at 24 weeks Type: treatment and preventiona	15	103	21	103	62	102
	Symptomatic only UTI (cystitis) Unit: time from prophylactic therapy start to cystitis symptoms onset, median (IQR) UTI defined as: 'cystitis' undefined Time: at 24 weeks Type: treatment and preventiona	43 (15 to 50)	103	24 (15 to 50)	103	28 (20 to 42)	102
Lopes de Carvalho 2012		D‐mannose 100 mg + cranberry 40 mg + vitamin C 60 mg		Placebo		‐		D‐mannose combined with dietary supplements versus placebo
	Symptomatic and bacteriuria‐confirmed UTI Unit: not clear from abstract UTI defined as: "urinary infections and urine cultures" Time: at 12 weeks Type: "treatment and prevention"	"a significant reduction in number of urinary infections and frequency in active group in respect to placebo group".	11	"a significant reduction in number of urinary infections and frequency in active group in respect to placebo group".	10	‐	‐
Palleschi 2017		D‐mannose 500 mg + N‐acetylcysteine 100 mg + Morinda citrifolia fruit extract 300 mg		Prulifloxacin 400 mg (antibiotic)		‐		D‐mannose combined with dietary supplements versus antibiotic
	Symptomatic and bacteriuria confirmed UTI Unit: number of patients reporting a UTI UTI defined as: "UTI incidence (symptomatic or asymptomatic) via urine cultures" Time: 15 days from treatment start Type: prevention (perioperative)	(Female) 1   (Male) 1	19   18	(Female) 1   (Male) 2	17   21	‐	‐
Porru 2014		D‐mannose 1 g		Trimethoprim 160 mg sulfamethoxazole 800 mg (antibiotics)		‐		D‐mannose versus antibiotics
	Symptomatic and bacteriuria‐confirmed UTI Unit: number of patients with a UTI UTI defined as: "acute flare of urinary symptoms + positive urine culture with at least 100,000 uropathogens per ml" Time: approximately 52 weeks Type: treatment and preventiona	No data available for first phase of cross‐over	60	No data available for first phase of cross‐over	60	‐	‐
	Symptomatic and bacteriuria‐confirmed UTI Unit: time to UTI recurrence, mean ± SD UTI defined as: "acute flare of urinary symptoms + positive urine culture with at least 100,000 uropathogens per ml" Time: approximately 52 weeks Type: treatment and preventiona	No data available for first phase of cross‐over	60	No data available for first phase of cross‐over	60	‐	‐
	Pain Unit: average VAS (1 to 10) pain and urgency scores per patient reported during UTI episodes, mean ± SD Time: approximately 52 weeks Type: treatment and preventiona	No data available for first phase of cross‐over	60	No data available for first phase of cross‐over	60	‐	‐
Russo 2019		Cranberry + D‐mannose + Boswellia + Curcuma + NoxamicineVR (Kistinox ActVR ) (doses not reported)		No treatment		‐		D‐mannose combined with dietary supplements versus no treatment
	Symptomatic and bacteriuria confirmed UTI Unit: Rate of UTI infections, cumulative incidence, unclear whether number of patients reporting or number reported per patient Defined as: symptoms + positive urine culture Time: 2 weeks postop Type: prevention (perioperative)	1	20	1	20	‐	‐
	Pain Unit: average VAS (scale size unclear) pain scores/patient reported postop, mean ± SD Time: 1 day postop Type: prevention (perioperative)	1.2 ± 1.1	20	1.3 ± 0.9	20	‐	‐
Salinas‐Casado 2018		D‐mannose 2 g, 24 hour prolonged release, associated with proanthocyanidin 140 mg + ursolic acid 7.98 mg + vitamin A (unknown dose) + vitamin C (unknown dose) + vitamin D (unknown dose) oligoelement zinc (unknown dose)		Proanthocyanidin 140 mg		‐		D‐mannose combined with dietary supplements versus dietary supplement
	Symptomatic and bacteriuria‐confirmed UTI Unit: patient Defined as: symptomatic UTI with reactive urine strip and urine culture Time: 24 weeks Type: prevention	24%	denominator is unclear	45%	denominator is unclear	‐	‐
Footnotes: a treatment and prevention: indicates that the patient population at enrolment were participants who had both an "acute symptomatic UTI and three or more UTIs documented with culture of midstream urine specimen at inclusion and in the preceding 12 months", or "baseline was women with acute cystitis (isolated bacteria) or history of recurrent cystitis (at least 2 episodes in 6 months or 3 in 12 months)". Therefore possible that participants had UTI at the start of treatment.   IQR: interquartile range; SD: standard deviation; UTI: urinary tract infection; VAS: visual analogue scale